Myriad was formed in 1991 as one of the first genomic companies with the vision of elucidating the role genes play in human disease, and using this critical information to improve patient healthcare by developing novel molecular diagnostic products. Our predictive medicine products are designed to assess an individual’s risk for developing disease, so action can be taken to prevent or delay the onset of disease. Our personalized medicine products identify a patient’s likelihood of responding to a particular therapy to ensure optimal treatment decisions. Finally, our prognostic medicine products assess a patient’s risk of disease progression and recurrence, so that a physician knows how aggressively to treat the patient’s disease.
Myriad scientists working with numerous collaborators from around the world have discovered many important disease-causing genes. A sample of Myriad’s discoveries include the:
- BRCA1 and BRCA2 hereditary breast and ovarian cancer genes
- p16 cell cycle control gene that increases the risk of developing a variety of cancers, notably melanoma
- PTEN tumor suppressor gene that is involved in the development of many cancers, and
- ELAC2 prostate cancer gene
In 1996, Myriad introduced the first molecular diagnostic test for a common disease: hereditary breast and ovarian cancer. Our first test, BRACAnalysis®, has become the standard of care and has been followed by eight additional innovative molecular diagnostic tests for breast, prostate, colon, pancreatic, ovarian, and uterine cancers and melanoma. Today, Myriad’s tests have benefited approximately one million cancer patients.
For over two decades, Myriad has been a pioneer in applying nucleic acid (DNA and RNA) technologies to identify novel genetic biomarkers that save lives and improve the quality of life of patients with cancer or who have a family history of cancer. In 2011, Myriad acquired Rules-Based Medicine, Inc. of Austin, Texas, a leader in utilizing multiplex immunoassay technologies to discover protein biomarkers. The ability to work with DNA, RNA and proteins gives Myriad a complete complement of biomarker technologies and positions the Company as a leader in the emerging field of companion diagnostics.
Myriad is building on this strong tradition by extending our mission worldwide, in an effort to broaden the Company’s geographic footprint and provide critical information to more patients and healthcare providers. Myriad tests are now available to patients in over 50 countries worldwide through our team of clinical support professionals and distributors. In addition to our kit manufacturing and product development laboratory in Koln, the Company has set up its European headquarters in Zurich, Switzerland and regional offices in France, UK, Spain, Italy, Germany, Austria, Canada, Australia and Japan.
Thanks to the dedication and passion of its employees, Myriad has received numerous awards acknowledging its life science innovations, contributions toward improving healthcare and philanthropy programs, including:
- Laguna Niguel 1997 Best of Biotech Award;
- Frost and Sullivan 2005 Diagnostic Player of the Year;
- American Federation for Aging Research 2008 Award of Distinction;
- Utah Philanthropy 2011 Corporate Spirit of Giving
- American Cancer Society of Utah 2012 Charles R. Smart Visionary Award.
- Forbes 2012 Top 50 Best Companies Under $1 Billion in Revenue.